Unique Imaging Findings of Neurologic Phantosmia Following Pfizer-BioNtech COVID-19 Vaccination: A Case Report
Graham Keir, Naomi I. Maria, Claudia Kirsch
Abstract
ABSTRACT: Olfactory dysfunction related to SARS-CoV-2 infection and COVID-19 disease is now well established in the literature. In December 2020, the FDA approved the Pfizer-BioNTech and Moderna vaccines for use in preventing COVID-19 in the United States. To the best of our knowledge, this is the first report of a phantosmia post-Pfizer COVID-19 vaccination, with positive magnetic resonance imaging radiographic findings in a patient with documented absence of infection by SARS-CoV-2 virus or concomitant sinonasal disease.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)MedicineMagnetic resonance imagingVaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakConcomitantPediatricsDiseaseVirologyPathologySurgeryRadiologyInfectious disease (medical specialty)OutbreakPeripheral Neuropathies and DisordersOlfactory and Sensory Function StudiesLong-Term Effects of COVID-19